Bevacizumab Treatment For Type 1 Retinopathy of Prematurity
Latest Information Update: 06 Nov 2023
At a glance
- Drugs Bevacizumab (Primary)
- Indications Retinopathy of prematurity
- Focus Therapeutic Use
- 30 Oct 2023 Planned End Date changed from 1 Jun 2024 to 1 Dec 2026.
- 30 Oct 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Apr 2025.
- 19 May 2022 Planned End Date changed from 1 Apr 2024 to 1 Jun 2024.